During the past decade, Haematologische/Onkologische Schwerpunktpraxis - Rostock conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 1 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Haematologische/Onkologische Schwerpunktpraxis - Rostock" #1 sponsor was "Boehringer Ingelheim" with 2 trials, followed by "German CLL Study Group" with 2 trials sponsored, "German High-Grade Non-Hodgkin's Lymphoma Study Group" with 1 trials sponsored, "Technical University of Munich" with 1 trials sponsored and "iOMEDICO AG" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Haematologische/Onkologische Schwerpunktpraxis - Rostock" #1 collaborator was "Roche Pharma AG" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Haematologische/Onkologische Schwerpunktpraxis - Rostock" are "Chronic Lymphocytic Leukemia" (2 trials), "Pulmonary Disease, Chronic Obstructive" (2 trials), "Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC" (1 trials), "Extensive-stage Small Cell Lung Cancer" (1 trials) and "Lymphoma" (1 trials). Many other conditions were trialed in "Haematologische/Onkologische Schwerpunktpraxis - Rostock" in a lesser frequency.

Most popular intervention types in "Haematologische/Onkologische Schwerpunktpraxis - Rostock" are "Drug" (6 trials), "Other" (2 trials), "Biological" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Fludarabine" (2 trials), "Chlorambucil" (1 trials), "Fludarabine plus Cyclophosphamide" (1 trials), "Long-acting muscarinic antagonist+ Long-acting beta2 adrenoceptor agonist" (1 trials) and "Pazopanib+Sorafenib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Haematologische/Onkologische Schwerpunktpraxis - Rostock" are 7 trials for "All" genders.

Currently, there are NaN active trials in "Haematologische/Onkologische Schwerpunktpraxis - Rostock". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Haematologische/Onkologische Schwerpunktpraxis - Rostock, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Haematologische/Onkologische Schwerpunktpraxis - Rostock, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".